Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Zero Formalin Specimen Preservation Solution for Formalin-Free Classrooms 2025-10-21 10:00
Shimadzu Asia Pacific Celebrates 150th Anniversary -A Century and a Half of Driving Healthcare and Technological Breakthroughs 2025-10-21 09:00
NSG Bio Launches NSG BioSuites at Geneo - A New Product, Largest Site, and Fourth Location in Singapore 2025-10-21 08:00
LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today 2025-10-21 01:11
Benchling Partners with Anthropic to Build a Bridge Between Science and AI 2025-10-21 00:00
TraceLink Recognized on Fast Company's Next Big Things in Tech List 2025-10-20 23:59
BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission 2025-10-20 20:09
Weaving a Network of Care Together: Jiahui International Hospital (Shanghai) and NYU Shanghai Unveil Cooperative Program 2025-10-20 20:03
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC 2025-10-20 17:06
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma 2025-10-20 14:58
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions 2025-10-20 14:00
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO 2025-10-20 13:59
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer 2025-10-20 13:21
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025 2025-10-20 13:15
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM 2025-10-20 10:36
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability 2025-10-20 09:00
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity 2025-10-20 08:10
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 2025-10-19 15:00
From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 2025-10-19 13:00
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO 2025-10-18 22:46
1 18 19 20 21 22 918